title: Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation.
abstract: The identification of driver mutations and drugs that inhibit their activity has been a major therapeutic advance for patients with advanced lung adenocarcinoma. Unfortunately, the success of these drugs is limited by the universal development of resistance. Treatment failure can result from inadequate drug exposure or selection of resistant malignant clones. Clinically distinct mechanisms of disease progression have been identified and can inform treatment decisions. Investigations into the biochemical mechanisms of tyrosine kinase inhibitor resistance may provide additional therapeutic targets by which the efficacy of targeted therapy can be improved.
authors.affiliation: Kevin Becker, Yiqing Xu, Division of Hematology and Oncology, Maimonides Cancer Center, Brooklyn, NY 11201, United States.
authors.forename: Kevin
authors.initials: K
authors.lastname: Becker
authors.affiliation: Kevin Becker, Yiqing Xu, Division of Hematology and Oncology, Maimonides Cancer Center, Brooklyn, NY 11201, United States.
authors.forename: Yiqing
authors.initials: Y
authors.lastname: Xu
keywords: Adenocarcinoma; Epidermal growth factor receptor mutation; Lung cancer; Resistance; Targeted therapy; Tyrosine kinase inhibitor